Literature DB >> 26776493

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.

Antonello Veccia1, Orazio Caffo1, Ugo De Giorgi2, Giuseppe Di Lorenzo3, Cinzia Ortega4, Florinda Scognamiglio5, Michele Aieta6, Gaetano Facchini7, Giovanni Mansueto8, Rodolfo Mattioli9, Giuseppe Procopio10, Vittorina Zagonel11, Alessandro D'Angelo12, Gilbert Spizzo13, Roberto Bortolus14, Maddalena Donini15, Giovanni Lo Re16, Francesco Massari17, Giovanni Vicario18, Paolo A Zucali19, Daniele Alesini20, Andrea Bonetti21, Claudia Mucciarini22, Maurizio Nicodemo23, Alfredo Berruti24, Lucia Fratino25, Michele Lodde26, Caterina Messina27, Alessandra Perin28, Daniele Santini29, Teodoro Sava30, Marcello Tucci31, Umberto Basso11, Francesca Maines1, Luca S Burgio2, Enzo Galligioni1.   

Abstract

AIM: To assess clinical outcomes in octogenarians treated with docetaxel (DOC) for metastatic castration-resistant prostate cancer. PATIENTS &
METHODS: The multicenter retrospective study was based on a review of the pre- and post-DOC clinical history, DOC treatment and outcomes.
RESULTS: We reviewed the records of 123 patients (median age: 82 years) who received DOC every 3 weeks or weekly, without significant grade 3-4 toxicities. Median progression-free survival was 7 months; median overall survival from the start of DOC was 20 months, but post-progression treatments significantly prolonged overall survival.
CONCLUSION: The findings of this study suggest that toxicity is acceptable, survival is independent of patient's age and survival can be significantly prolonged by the use of new agents.

Entities:  

Keywords:  castration-resistant prostate cancer; docetaxel; elderly; geriatric assessment

Mesh:

Substances:

Year:  2016        PMID: 26776493     DOI: 10.2217/fon.15.302

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  4 in total

Review 1.  Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions.

Authors:  Orazio Caffo; Francesca Maines; Mimma Rizzo; Stefania Kinspergher; Antonello Veccia
Journal:  Clin Interv Aging       Date:  2016-12-22       Impact factor: 4.458

Review 2.  Micrornas in prostate cancer: an overview.

Authors:  Daniela Vanacore; Mariarosaria Boccellino; Sabrina Rossetti; Carla Cavaliere; Carmine D'Aniello; Rossella Di Franco; Francesco Jacopo Romano; Micaela Montanari; Elvira La Mantia; Raffaele Piscitelli; Flavia Nocerino; Francesca Cappuccio; Giovanni Grimaldi; Alessandro Izzo; Luigi Castaldo; Maria Filomena Pepe; Maria Gabriella Malzone; Gelsomina Iovane; Gianluca Ametrano; Paola Stiuso; Lucio Quagliuolo; Daniela Barberio; Sisto Perdonà; Paolo Muto; Maurizio Montella; Piera Maiolino; Bianca Maria Veneziani; Gerardo Botti; Michele Caraglia; Gaetano Facchini
Journal:  Oncotarget       Date:  2017-07-25

Review 3.  Detection and Prognosis of Prostate Cancer Using Blood-Based Biomarkers.

Authors:  Wei Jin; Xiang Fei; Xia Wang; Yan Song; Fangjie Chen
Journal:  Mediators Inflamm       Date:  2020-05-04       Impact factor: 4.711

4.  Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer.

Authors:  Manuel Caitano Maia; Allan A Lima Pereira; Liana Valente Lage; Natalia Moreno Fraile; Victor Van Vaisberg; Guilherme Kudo; Romualdo Barroso-Sousa; Diogo Assed Bastos; Carlos Dzik
Journal:  J Glob Oncol       Date:  2017-03-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.